+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Advanced Therapy Medicinal Products CDMO Market by Product, Phase, Indication, and by Region - Global Forecast to 2022-2033

  • PDF Icon

    Report

  • 200 Pages
  • January 2023
  • Region: Global
  • Quintana Research and Consulting
  • ID: 5717239
The advanced therapy medicinal products CDMO market size is estimated to be USD 4,987.1 million in 2022 and is expected to witness a CAGR of 18.97% during the forecast period 2023-2033. Rare & life-threatening disorders including metabolic and ocular disease, and surge in investment in R&D of advanced treatment medicinal products are some of the factors contributing to the market growth. Furthermore, increase in R&D investment flow and growing number of clinical studies for advanced therapy medical products (ATMPs) are other factors supporting the market growth. However, strict regulations and high price of outsourcing is expected to hinder the growth.

Increase in R&D investment flow is expected to fuel the market growth during the projected period due to the intense rivalry among the major companies to acquire a significant portion of the market. For instance, Excellos, a CDMO for cell therapy, reported in January 2022 that it had closed a USD 15 million financing round from Telegraph Hill Partners. The company works with doctors and scientists developing cell and gene therapies to provide cGMP cellular services and products, along with manufacturing and process development expertise.

Growing number of clinical studies for advanced therapy medical products (ATMPs) is predicted to propel the market growth during the forecast period. There were 3,579 gene, cell, and RNA therapies in development as of Q1 2022, according to a study by the American Society of Gene and Cell Therapy. According to the research, as of Q1 2021, the pipeline for gene cell therapy has grown by 16%. Genetically engineered cell therapies are being exceeded by CAR-T cell therapies in the development. Additionally, 98% of CAR-T cell treatments are being developed with a cancer indication.

Segmentation

By Product

The market is categorized into tissue engineered, cell therapy, gene therapy, and others. In 2022, the gene therapy segment accounted for the highest revenue share due to the increase in financial support and a growth in the quantity of clinical trials for gene treatments. Gene treatments received about USD 12 billion in funding during the first three quarters of 2020, and about 370 clinical trials are now being conducted. Around 2,000 gene therapies were also in development by the middle of 2022, with many different therapeutic areas including cardiovascular, neurological, cancer, blood, and infectious diseases as their targets. The market for cell therapy is anticipated to develop at the fastest rate over the projected period. With the addition of new cell types, the field of cellular treatments is continually developing, which presents numerous potentials for businesses to strengthen their market positions. Additionally, the market is attracting new players as a result of the significant unmet need for cell therapy manufacturing, the recent approval of advanced medicines, and the products' established efficacy.

By Phase

The market is divided into phase I, phase II, phase III, phase IV. In the global market, the phase I segment accounted for the largest revenue share in 2022 owing to expanding R&D efforts and the rise in the number of human trials for cutting-edge therapies. Phase 1 aids in ensuring that a drug is safe as it is given to a small number of patients in various doses and dosing formats. The major goal of this phase is to ascertain the largest dose a patient can take without experiencing any adverse effects. Phase 1 drugs that advance to the next stage are about 70%. The phase 2 segment is expected to grow significantly over the course of the projected period. Phase 2 clinical studies contain the majority of emerging ATMPs due to high clearance rate of phase 1 clinical studies. According to data from the Alliance for Regenerative Medicine, more than 2,093 clinical trials are now being conducted worldwide as of June 2022, with 1,117 of such trials (or 53% of them) being in phase II.

By Indication

The market is segmented into cardiology, musculoskeletal, oncology, central nervous system, dermatology, endocrine, metabolic, genetic, infectious disease, immunology & inflammation, hematology, gastroenterology, ophthalmology, and others. In 2022, the oncology segment accounted for the largest revenue share owing to burden of disease, key players' strategic planning, and the availability of cutting-edge therapies used for treating various cancer indications Approximately 18,000 to 19,000 patients and 124,000 patients, respectively, were projected to be patients for cancer treatment using the cell & gene therapy products Kymriah (Novartis AG) and Yescarta (Gilead Sciences, Inc.).The cardiology segment is anticipated to have significant increase over the time of the forecast. This is due to the rising incidence of cardiovascular diseases and the partnership in research for the development of cutting-edge treatments. For instance, Trizell GmbH and Catalent, Inc. partnered to develop a phase 1 cell treatment to treat micro- and macroangiopathy in February 2021. The drug produced by Trizell is an Advanced Therapy Medicinal Product (ATMP) that makes use of German-developed platform technology named regulatory macrophages.

Regional Markets

In 2022, North America region accounted for the highest revenue in the advanced therapy medicinal products CDMO market and is expected to maintain its dominance during the forecast period. This is attributed to the rising interest in advanced therapies and growing outsourcing activities. It is projected that America will maintain its position as a global leader in R&D for cutting-edge treatments during the forecast period. Investments in the regional advanced treatment medical products CDMO industry have accelerated in response to recent approvals of products including Kymriah and Yescarta. Additionally, the U.S. FDA approved Abecma in March 2021, making it the first CAR-T cell therapy approved for the treatment of cancer. Asia Pacific is anticipated to have the fastest growth rate among the regions throughout the forecast period due to the rising demand for novel ATMPs and the expanding R&D activity to create novel therapies. Additionally, the country's rising CDMO services are a major factor in the expansion of the market for advanced therapeutic medical items. In the advancement of mesenchymal stem cell research and therapies, a number of domestic players have partnered with biotech companies from other nations. Furthermore, Takara Bio, Inc. introduced CDMO services for gene therapy products using siTCR technology for its genetic modification T-cell therapy products in September 2022.

Competitor Insights

Some of the key players operating in the advanced therapy medicinal products CDMO market are BlueReg, Minaris Regenerative Medicine, Lonza, CGT Catapult, Bio Elpida, AGC Biologics, Rentschler Biopharma SE, Catalent, WuXi Advanced Therapies, Celonic, and Patheon.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

  • Pfizer declared the start of its unit for a phase III trial of experimental gene therapy for people with Duchenne muscular dystrophy in April 2022.
  • Additionally, Recipharm AB finalised the acquisition of Vibalogics in February 2022. With the help of Vibalogics' expertise in viral vaccines, oncolytic viruses, and viral vector gene therapy, Recipharm will be able to give a high level of diversity through many technologies and modalities.
This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, phase, and indication from 2023 to 2033.

Segmentation: Advanced Therapy Medicinal Products CDMO Market Report 2022 - 2033

Product (Revenue, USD Million), 2022 - 2033

  • Tissue Engineered
  • Cell Therapy
  • Gene Therapy
  • Others

Phase (Revenue, USD Million), 2022 - 2033

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Indication (Revenue, USD Million), 2022 - 2033

  • Cardiology
  • Musculoskeletal
  • Oncology
  • Central Nervous System
  • Dermatology
  • Endocrine
  • Metabolic
  • Genetic
  • Infectious Disease
  • Immunology & Inflammation
  • Hematology
  • Gastroenterology
  • Ophthalmology
  • Others

By Region (Revenue, USD Million), 2022 - 2033

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM

Middle East & Africa

  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Framework
1.3.1. Research Models
1.3.1.1. Bottom-up Approach
1.3.1.2. Top-down Approach
1.3.1.3. Data Triangulation
1.3.2. Data Analysis
1.3.2.1. Data Validation
1.3.2.2. Market Size Estimation
1.3.2.3. Market Forecast Model

2. Introduction: Advanced Therapy Medicinal Products CDMO

3. Executive Summary

4. Market Dynamics
4.1. Market Drivers
4.1.1. Driver 1
4.1.2. Driver 2
4.1.3. Driver 3
4.1.4. Driver 4
4.2. Market Restraint
4.2.1. Restraint 1
4.2.2. Restraint 2
4.2.3. Restraint 3
4.3. Market Opportunities
4.3.1. Opportunity 1
4.3.2. Opportunity 2
4.3.3. Opportunity 3
4.4. Market Trends
4.4.1. Trend 1
4.4.2. Trend 2
4.4.3. Trend 3
4.5. Market Challenges
4.5.1. Challenge 1
4.5.2. Challenge 2
4.5.3. Challenge 3

5. Market Environment Analysis
5.1. Porter’s 5 Forces Analysis
5.2. PESTEL Analysis
5.3. SWOT Analysis

6. COVID-19 Impact Analysis: Advanced Therapy Medicinal Products CDMO Market

7. Market Analysis by Product
7.1. Tissue Engineered
7.1.1. Tissue Engineered Market Forecast, 2022-2033 (USD Million)
7.2. Cell Therapy
7.2.1. Cell Therapy Market Forecast, 2022-2033 (USD Million)
7.3. Gene Therapy
7.3.1. Gene Therapy Market Forecast, 2022-2033 (USD Million)
7.4. Others
7.4.1. Others Market Forecast, 2022-2033 (USD Million)

8. Market Analysis by Phase
8.1. Phase I
8.1.1. Phase I Market Forecast, 2022-2033 (USD Million)
8.2. Phase II
8.2.1. Phase II Market Forecast, 2022-2033 (USD Million)
8.3. Phase III
8.3.1. Phase III Market Forecast, 2022-2033 (USD Million)
8.4. Phase IV
8.4.1. Phase IV Market Forecast, 2022-2033 (USD Million)

9. Market Analysis by Indication
9.1. Cardiology
9.1.1. Cardiology Market Forecast, 2022-2033 (USD Million)
9.2. Musculoskeletal
9.2.1. Musculoskeletal Market Forecast, 2022-2033 (USD Million)
9.3. Oncology
9.3.1. Oncology Market Forecast, 2022-2033 (USD Million)
9.4. Central Nervous System
9.4.1. Central Nervous System Market Forecast, 2022-2033 (USD Million)
9.5. Dermatology
9.5.1. Dermatology Market Forecast, 2022-2033 (USD Million)
9.6. Endocrine
9.6.1. Endocrine Market Forecast, 2022-2033 (USD Million)
9.7. Metabolic
9.7.1. Metabolic Market Forecast, 2022-2033 (USD Million)
9.8. Genetic
9.8.1. Genetic Market Forecast, 2022-2033 (USD Million)
9.9. Infectious Disease
9.9.1. Infectious Disease Market Forecast, 2022-2033 (USD Million)
9.10. Immunology & Inflammation
9.10.1. Immunology & Inflammation Market Forecast, 2022-2033 (USD Million)
9.11. Hematology
9.11.1. Hematology Market Forecast, 2022-2033 (USD Million)
9.12. Gastroenterology
9.12.1. Gastroenterology Market Forecast, 2022-2033 (USD Million)
9.13. Ophthalmology
9.13.1. Ophthalmology Market Forecast, 2022-2033 (USD Million)
9.14. Others
9.14.1. Others Market Forecast, 2022-2033 (USD Million)

8. Regional Market Analysis
8.1. Regional Market Trends Analysis

9. North America Advanced Therapy Medicinal Products CDMO Market
9.1. North America Advanced Therapy Medicinal Products CDMO Market
9.1.1. North America Market Size and Forecast, 2022-2033 (USD Million)
9.1.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
9.1.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
9.1.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
9.2. U.S. Advanced Therapy Medicinal Products CDMO Market
9.2.1. U.S. Market Size and Forecast, 2022-2033 (USD Million)
9.2.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
9.2.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
9.2.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
9.3. Canada Advanced Therapy Medicinal Products CDMO Market
9.3.1. Canada Market Size and Forecast, 2022-2033 (USD Million)
9.3.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
9.3.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
9.3.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)

10. Europe Advanced Therapy Medicinal Products CDMO Market
10.1. Europe Advanced Therapy Medicinal Products CDMO Market
10.1.1. Europe Market Size and Forecast, 2022-2033 (USD Million)
10.1.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
10.1.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
10.1.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
10.2. Germany Advanced Therapy Medicinal Products CDMO Market
10.2.1. Germany Market Size and Forecast, 2022-2033 (USD Million)
10.2.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
10.2.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
10.2.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
10.3. UK Advanced Therapy Medicinal Products CDMO Market
10.3.1. UK Market Size and Forecast, 2022-2033 (USD Million)
10.3.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
10.3.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
10.3.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
10.4. France Advanced Therapy Medicinal Products CDMO Market
10.4.1. France Market Size and Forecast, 2022-2033 (USD Million)
10.4.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
10.4.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
10.4.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
10.5. Spain Advanced Therapy Medicinal Products CDMO Market
10.5.1. Spain Market Size and Forecast, 2022-2033 (USD Million)
10.5.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
10.5.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
10.5.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
10.6. Italy Advanced Therapy Medicinal Products CDMO Market
10.6.1. Italy Market Size and Forecast, 2022-2033 (USD Million)
10.6.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
10.6.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
10.6.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
10.7. Rest of Europe Advanced Therapy Medicinal Products CDMO Market
10.7.1. Rest of Europe Market Size and Forecast, 2022-2033 (USD Million)
10.7.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
10.7.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
10.7.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)

11. Asia Pacific Advanced Therapy Medicinal Products CDMO Market
11.1. Asia Pacific Advanced Therapy Medicinal Products CDMO Market
11.1.1. Asia Pacific Market Size and Forecast, 2022-2033 (USD Million)
11.1.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
11.1.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
11.1.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
11.2. Japan Advanced Therapy Medicinal Products CDMO Market
11.2.1. Japan Market Size and Forecast, 2022-2033 (USD Million)
11.2.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
11.2.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
11.2.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
11.3. China Advanced Therapy Medicinal Products CDMO Market
11.3.1. China Market Size and Forecast, 2022-2033 (USD Million)
11.3.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
11.3.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
11.3.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
11.4. India Advanced Therapy Medicinal Products CDMO Market
11.4.1. India Market Size and Forecast, 2022-2033 (USD Million)
11.4.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
11.4.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
11.4.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
11.5. South Korea Advanced Therapy Medicinal Products CDMO Market
11.5.1. South Korea Market Size and Forecast, 2022-2033 (USD Million)
11.5.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
11.5.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
11.5.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
11.6. Australia Advanced Therapy Medicinal Products CDMO Market
11.6.1. Australia Market Size and Forecast, 2022-2033 (USD Million)
11.6.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
11.6.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
11.6.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
11.7. Rest of Asia Pacific Advanced Therapy Medicinal Products CDMO Market
11.7.1. Rest of Asia Pacific Market Size and Forecast, 2022-2033 (USD Million)
11.7.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
11.7.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
11.7.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)

12. Latin America Advanced Therapy Medicinal Products CDMO Market
12.1. Latin America Advanced Therapy Medicinal Products CDMO Market
12.1.1. Latin America Market Size and Forecast, 2022-2033 (USD Million)
12.1.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
12.1.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
12.1.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
12.2. Brazil Advanced Therapy Medicinal Products CDMO Market
12.2.1. Brazil Market Size and Forecast, 2022-2033 (USD Million)
12.2.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
12.2.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
12.2.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
12.3. Mexico Advanced Therapy Medicinal Products CDMO Market
12.3.1. Mexico Market Size and Forecast, 2022-2033 (USD Million)
12.3.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
12.3.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
12.3.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
12.4. Argentina Advanced Therapy Medicinal Products CDMO Market
12.4.1. Argentina Market Size and Forecast, 2022-2033 (USD Million)
12.4.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
12.4.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
12.4.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
12.5. Rest of Latin America Advanced Therapy Medicinal Products CDMO Market
12.5.1. Rest of Latin America Market Size and Forecast, 2022-2033 (USD Million)
12.5.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
12.5.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
12.5.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)

13. MEA Advanced Therapy Medicinal Products CDMO Market
13.1. MEA Advanced Therapy Medicinal Products CDMO Market
13.1.1. MEA Market Size and Forecast, 2022-2033 (USD Million)
13.1.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
13.1.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
13.1.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
13.2. GCC Advanced Therapy Medicinal Products CDMO Market
13.2.1. GCC Market Size and Forecast, 2022-2033 (USD Million)
13.2.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
13.2.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
13.2.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
13.3. South Africa Advanced Therapy Medicinal Products CDMO Market
13.3.1. South Africa Market Size and Forecast, 2022-2033 (USD Million)
13.3.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
13.3.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
13.3.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)
13.4. Rest of MEA Advanced Therapy Medicinal Products CDMO Market
13.4.1. Rest of MEA Market Size and Forecast, 2022-2033 (USD Million)
13.4.1.1. Market Size and Forecast by Product, 2022-2033 (USD Million)
13.4.1.2. Market Size and Forecast by Phase, 2022-2033 (USD Million)
13.4.1.3. Market Size and Forecast by Indication, 2022-2033 (USD Million)

14. Competitor Analysis
14.1. Market Share Analysis, 2022
14.2. Major Recent Developments, 2019-2022

15. Company Profiles
15.1. BlueReg
15.1.1. Company Snapshot
15.1.2. Company Overview
15.1.3. Financial Analysis
15.1.4. Product Benchmarking
15.1.5. Recent Developments
15.2. Minaris Regenerative Medicine
15.2.1. Company Snapshot
15.2.2. Company Overview
15.2.3. Financial Analysis
15.2.4. Product Benchmarking
15.2.5. Recent Developments
15.3. Lonza
15.3.1. Company Snapshot
15.3.2. Company Overview
15.3.3. Financial Analysis
15.3.4. Product Benchmarking
15.3.5. Recent Developments
15.4. CGT Catapult
15.4.1. Company Snapshot
15.4.2. Company Overview
15.4.3. Financial Analysis
15.4.4. Product Benchmarking
15.4.5. Recent Developments
15.5. Bio Elpida
15.5.1. Company Snapshot
15.5.2. Company Overview
15.5.3. Financial Analysis
15.5.4. Product Benchmarking
15.5.5. Recent Developments
15.6. AGC Biologics
15.6.1. Company Snapshot
15.6.2. Company Overview
15.6.3. Financial Analysis
15.6.4. Product Benchmarking
15.6.5. Recent Developments
15.7. Rentschler Biopharma SE
15.7.1. Company Snapshot
15.7.2. Company Overview
15.7.3. Financial Analysis
15.7.4. Product Benchmarking
15.7.5. Recent Developments
15.8. Catalent
15.8.1. Company Snapshot
15.8.2. Company Overview
15.8.3. Financial Analysis
15.8.4. Product Benchmarking
15.8.5. Recent Developments
15.9. WuXi Advanced Therapies
15.9.1. Company Snapshot
15.9.2. Company Overview
15.9.3. Financial Analysis
15.9.4. Product Benchmarking
15.9.5. Recent Developments
15.10. Celonic
15.10.1. Company Snapshot
15.10.2. Company Overview
15.10.3. Financial Analysis
15.10.4. Product Benchmarking
15.10.5. Recent Developments
15.11. Patheon
15.11.1. Company Snapshot
15.11.2. Company Overview
15.11.3. Financial Analysis
15.11.4. Product Benchmarking
15.11.5. Recent Developments
15.12. Company 12
15.12.1. Company Snapshot
15.12.2. Company Overview
15.12.3. Financial Analysis
15.12.4. Product Benchmarking
15.12.5. Recent Developments
15.13. Company 13
15.13.1. Company Snapshot
15.13.2. Company Overview
15.13.3. Financial Analysis
15.13.4. Product Benchmarking
15.13.5. Recent Developments
15.14. Company 14
15.14.1. Company Snapshot
15.14.2. Company Overview
15.14.3. Financial Analysis
15.14.4. Product Benchmarking
15.14.5. Recent Developments
15.15. Company 15
15.15.1. Company Snapshot
15.15.2. Company Overview
15.15.3. Financial Analysis
15.15.4. Product Benchmarking
15.15.5. Recent Developments

16. Conclusion

17. Recommendations

Companies Mentioned

A selection of companies mentioned in this report includes:

  • BlueReg
  • Minaris Regenerative Medicine
  • Lonza
  • CGT Catapult
  • Bio Elpida
  • AGC Biologics
  • Rentschler Biopharma SE
  • Catalent
  • WuXi Advanced Therapies
  • Celonic
  • Patheon.